142 related articles for article (PubMed ID: 30819637)
1. Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy.
Taylor MA; Alemozaffar M; Master VA; Sanda MG; Filson CP
Clin Genitourin Cancer; 2019 Jun; 17(3):e494-e504. PubMed ID: 30819637
[TBL] [Abstract][Full Text] [Related]
2. [The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer].
Heidenreich A; Ohlmann CH
Aktuelle Urol; 2005 Jun; 36(3):219-29. PubMed ID: 16001337
[TBL] [Abstract][Full Text] [Related]
3. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.
Yuh BE; Ruel NH; Mejia R; Novara G; Wilson TG
BJU Int; 2013 Jul; 112(1):81-8. PubMed ID: 23351148
[TBL] [Abstract][Full Text] [Related]
4. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
6. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
7. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
[TBL] [Abstract][Full Text] [Related]
8. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
9. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
[TBL] [Abstract][Full Text] [Related]
10. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
Heidenreich A; Varga Z; Von Knobloch R
J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
[TBL] [Abstract][Full Text] [Related]
11. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
[TBL] [Abstract][Full Text] [Related]
12. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic value of lymph node dissection at radical prostatectomy: a population-based case-cohort study.
Withrow DR; DeGroot JM; Siemens DR; Groome PA
BJU Int; 2011 Jul; 108(2):209-16. PubMed ID: 21044247
[TBL] [Abstract][Full Text] [Related]
14. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
[TBL] [Abstract][Full Text] [Related]
15. Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer.
Friedlander DF; Krimphove MJ; Cole AP; Tully KH; Lipsitz SR; Kibel AS; Kilbridge KL; Trinh QD
Ann Surg Oncol; 2020 Jun; 27(6):1929-1936. PubMed ID: 31848818
[TBL] [Abstract][Full Text] [Related]
16. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
Tsurusaki T; Yamasaki Y; Maruta S
Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
[TBL] [Abstract][Full Text] [Related]
17. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.
Hayn MH; Orom H; Shavers VL; Sanda MG; Glasgow M; Mohler JL; Underwood W
Cancer; 2011 Oct; 117(20):4651-8. PubMed ID: 21456009
[TBL] [Abstract][Full Text] [Related]
18. Current controversies on the role of lymphadenectomy for prostate cancer.
Chalouhy C; Gurram S; Ghavamian R
Urol Oncol; 2019 Mar; 37(3):219-226. PubMed ID: 30579787
[TBL] [Abstract][Full Text] [Related]
19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
20. Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy.
Heidenreich A; Pfister D; Thüer D; Brehmer B
BJU Int; 2011 Jan; 107(2):220-5. PubMed ID: 20590538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
